Evidence map›Paper›PMID 40016284›Full record

ArticleCommunications biology2025

FABP5 is a key player in metabolic modulation and NF-κB dependent inflammation driving pleural mesothelioma.

Eleonora Vecchio, Raffaella Gallo, Selena Mimmi, Debora Gentile, Caterina Giordano, Emilio Straface, Rossana Marino, Carmen Caiazza, Arianna Pastore, Maria Rosaria Ruocco and 10 more

Abstract read
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Eleonora Vecchio *Department of Experimental and Clinical Medicine, University of Catanzaro "Magna Graecia", Catanzaro, Italy.
Raffaella Gallo *Department of Experimental and Clinical Medicine, University of Catanzaro "Magna Graecia", Catanzaro, Italy.
Selena Mimmi *Department of Experimental and Clinical Medicine, University of Catanzaro "Magna Graecia", Catanzaro, Italy.
Debora GentileDepartment of Experimental and Clinical Medicine, University of Catanzaro "Magna Graecia", Catanzaro, Italy.ORCID http://orcid.org/0000-0003-3541-1830
Caterina GiordanoDepartment of Experimental and Clinical Medicine, University of Catanzaro "Magna Graecia", Catanzaro, Italy.ORCID http://orcid.org/0000-0001-8681-8230
Emilio StrafaceDepartment of Experimental and Clinical Medicine, University of Catanzaro "Magna Graecia", Catanzaro, Italy.ORCID http://orcid.org/0009-0004-4583-863X
Rossana MarinoDepartment of Molecular Medicine and Medical Biotechnology, University of Naples "Federico II", Naples, Italy.
Carmen CaiazzaDepartment of Molecular Medicine and Medical Biotechnology, University of Naples "Federico II", Naples, Italy.
Arianna PastoreDepartment of Pharmacy, University of Naples Federico II, Naples, Italy.
Maria Rosaria RuoccoDepartment of Molecular Medicine and Medical Biotechnology, University of Naples "Federico II", Naples, Italy.
Alessandro ArcucciDepartment of Public Health, University of Naples "Federico II", Naples, Italy.
Marco SchiavoneDepartment of Molecular and Translational Medicine, Zebrafish Facility, University of Brescia, Brescia, Italy.
Camillo PalmieriDepartment of Experimental and Clinical Medicine, University of Catanzaro "Magna Graecia", Catanzaro, Italy.ORCID http://orcid.org/0000-0001-6707-4723
Enrico IaccinoDepartment of Experimental and Clinical Medicine, University of Catanzaro "Magna Graecia", Catanzaro, Italy.
Mariano StornaiuoloDepartment of Pharmacy, University of Naples Federico II, Naples, Italy.
Ileana QuintoDepartment of Experimental and Clinical Medicine, University of Catanzaro "Magna Graecia", Catanzaro, Italy.
Massimo MallardoDepartment of Molecular Medicine and Medical Biotechnology, University of Naples "Federico II", Naples, Italy.ORCID http://orcid.org/0000-0002-4001-3856
Fernanda MartiniDepartment of Medical Sciences, University of Ferrara, Ferrara, Italy.
Mauro TognonDepartment of Medical Sciences, University of Ferrara, Ferrara, Italy.
Giuseppe FiumeDepartment of Experimental and Clinical Medicine, University of Catanzaro "Magna Graecia", Catanzaro, Italy. fiume@unicz.it.ORCID http://orcid.org/0000-0002-5414-6190

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pleural mesothelioma (PM) poses a significant challenge in oncology due to its intricate molecular and metabolic landscape, chronic inflammation, and heightened oxidative stress, which contribute to its notorious resilience and clinical complexities. Despite advancements, the precise mechanisms driving PM carcinogenesis remain elusive, impeding therapeutic progress. Here, we explore the interplay between tumor growth dynamics, lipid metabolism, and NF-κB dysregulation in malignant pleural mesothelioma, shedding light on novel molecular mechanisms underlying its pathogenesis. Our study reveals distinctive growth dynamics in PM cells, characterized by heightened proliferation, altered cell cycle progression, and resistance to apoptosis. Intriguingly, PM cells exhibit increased intracellular accumulation of myristic, palmitic, and stearic acids, suggestive of augmented lipid uptake and altered biosynthesis. Notably, we identify FABP5 as a key player in driving metabolic alterations and inflammation through NF-κB dysregulation in mesothelioma cells, distinguishing them from normal mesothelial cells. Silencing of FABP5 leads to significant alterations in cell dynamics, metabolism, and NF-κB activity, highlighting its potential as a therapeutic target. Our findings unveil a reciprocal relationship between lipid metabolism and inflammation in PM, providing a foundation for targeted therapeutic strategies. Overall, this comprehensive investigation offers insights into the intricate molecular mechanisms driving PM pathogenesis and identifies potential avenues for therapeutic intervention.

Indexed as

Fatty Acid-Binding ProteinsInflammationLung NeoplasmsMesotheliomaMesothelioma, MalignantNF-kappa BPleural NeoplasmsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansLipid MetabolismFABP5 protein, humanFatty Acid-Binding ProteinsNF-kappa B

Identifiers

PMID40016284
PMCPMC11868402

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.